| New antithrombotic agents in acute coronary syndromes. | |
| | |
MedLine Citation:
|
PMID: 19395952 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Acute coronary syndromes still account for high mortality in many countries. Antithrombotic therapy represents a cornerstone in the therapy of acute coronary syndromes. Recent research has focussed on improving anti-ischemic potency and reducing bleeding complications as well as improving predictability of antithrombotic efficacy. RECENT FINDINGS: New antithrombotic drugs such as the factor Xa antagonists and the direct thrombin inhibitors have been developed and evaluated in clinical trials. Fondaparinux and bivalirudin are approved for clinical use in acute coronary syndromes. They improve the risk/benefit ratio and make routine control of their antithrombotic effect unnecessary. Other agents are being developed to further improve and facilitate antithrombotic therapy in acute coronary syndromes. SUMMARY: Antithrombotic therapy is essential in acute coronary syndrome. New drugs are being developed to enter clinical practice and improve efficacy and safety of this therapeutic strategy. |
| | |
Authors:
|
Martin Moser; Christoph Bode |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in cardiology Volume: 24 ISSN: 1531-7080 ISO Abbreviation: Curr. Opin. Cardiol. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8608087 Medline TA: Curr Opin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 313-7 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University of Freiburg, Freiburg, Germany. Martin.Moser@uniklinik-freiburg.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence for a lower target blood pressure for people with heart disease.
Next Document: Resistant hypertension: who and how to evaluate.